News & Updates

Treatment with the combination of ribociclib plus binimetinib appears to be well tolerated and delivers modest clinical activity in patients with locally advanced or metastatic melanoma harbouring NRAS mutation, according to the results of a phase Ib/II study.

A novel nitric oxide-releasing gel, berdazimer 10.3%, proves effective in the treatment of patients with water warts or molluscum contagiosum skin infection, facilitating clearance of lesions with low adverse event rates, as shown in the phase III B-SIMPLE4 trial.

Real-world patients with psoriatic arthritis (PsA) who received and remained on secukinumab treatment for 6 months has attained minimal disease activity (MDA) and shown improvements in clinical manifestations, patient-reported outcomes, and work productivity at follow-up, reveals a study. The results are consistent with findings from clinical trials.

Once-weekly treatment with tirzepatide in adults with obesity appears to yield substantial and sustained reductions in body weight, according to the phase III SURMOUNT-1 trial.

Treatment with tenofovir alafenamide (TAF) results in similar virological response compared with tenofovir disoproxil fumarate (TDF) in treatment-naïve patients with chronic hepatitis B (CHB), according to a real-world study from Korea presented at ILC 2022.

In the treatment of patients with drug-resistant focal epilepsy, transdermally administered cannabidiol is well tolerated but is not superior to placebo in terms of reducing seizure frequency, according to a study.

Safety analysis of the phase III MAESTRO-NAFLD-1 trial presented at ILC 2022 demonstrated the potential of resmetirom as a treatment for patients with non-alcoholic steatohepatitis (NASH) who have liver fibrosis.